PROCEPT BioRobotics Stock: Surgical Robots For Urology
Breaking news this week. Elizabeth Holmes of Theranos is formulating her “bad man made me do it” defense, and her attorneys are considering whether or not she should take the stand. Having her stare at the jury with those Manson lamps while articulating, in that truck-driver voice, why her behavior wasn’t totally psychopathic makes about as much sense as trying to invade Russia in wintertime.
Theranos was able to dupe some of the world’s most sophisticated investors because early-stage investments are often nothing but exciting stories investors believe in. The only way to demonstrate product-market fit is by showing meaningful revenues, a number we’ve pegged at $10 million annually. You can avoid Theranos types by only investing in firms with meaningful revenues. Today’s company, PROCEPT BioRobotics, just broke through that threshold halfway through this year by selling the first FDA-granted robotic surgery platform for the treatment of enlarged prostates. And now, they’re going public.
About PROCEPT BioRobotics Stock
We first came across
